Systemic treatment of metastatic cancer with platelet factor 4

Details Systemic treatment of metastatic cancer with platelet factor 4 Systemic treatment of metastatic cancer with platelet factor 4

1990-10-19

1994-02-08

Nucker, Christine M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

424 88, 435 696, 514 2, 530324, 530380, A61K 3702, A61K 3514

Patent

active

052848272

ABSTRACT:
The subject invention concerns a novel treatment for cancer. Specifically, the invention concerns the systemic administration of recombinant Platelet Factor Four (rPF4) to inhibit tumor growth in a mammal having metastatic cancer.

REFERENCES:
patent: 4645828 (1987-02-01), Twardzik
patent: 5086164 (1992-02-01), Malone et al.
Folkman, J. et al. 1983 Ciba Found Sympos. 100: 132-49. "The role of heparin in angiogenesis."

Affiliated with

Also associated with

Rating

Systemic treatment of metastatic cancer with platelet factor 4 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Systemic treatment of metastatic cancer with platelet factor 4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systemic treatment of metastatic cancer with platelet factor 4 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-697877